ARWR Key Statistics, Chart & Performance
The current stock price of ARWR is 70.105 USD. In the past month the price increased by 2.78%. In the past year, price increased by 247.69%.
ARWR Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to ARWR. When comparing the yearly performance of all stocks, ARWR is one of the better performing stocks in the market, outperforming 98.33% of all stocks.
ARWR Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to ARWR. ARWR has only an average score on both its financial health and profitability.
ARWR Financial Highlights
Over the last trailing twelve months ARWR reported a non-GAAP Earnings per Share(EPS) of -0.08. The EPS increased by 98.4% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -0.12% | ||
| ROE | -0.35% | ||
| Debt/Equity | 1.25 |
ARWR Forecast & Estimates
20 analysts have analysed ARWR and the average price target is 77.6 USD. This implies a price increase of 10.69% is expected in the next year compared to the current price of 70.105.
For the next year, analysts expect an EPS growth of -4191.43% and a revenue growth -47.26% for ARWR
ARWR Ownership
About ARWR
Company Profile
Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The company is headquartered in Pasadena, California and currently employs 711 full-time employees. The firm's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The firm's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. The company is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. The company has around 16 clinical-stage investigational medicines (wholly owned and partnered), which range in development stage from Phase I to Phase III. The firm's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MMP7, GSK-4532990, Fazirsiran, GSK5637608, ARO-CFB, ARO-INHBE, ARO-C3, ARO-PNPLA3, ARO-DUX4, ARO-DM1 and ARO-ATXN2.
Company Info
ARROWHEAD PHARMACEUTICALS IN
177 E Colorado Blvd, Suite 700
Pasadena CALIFORNIA 91105 US
CEO: Christopher Anzalone
Employees: 711
Phone: 16266964702
ARROWHEAD PHARMACEUTICALS IN / ARWR FAQ
What does ARWR do?
Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The company is headquartered in Pasadena, California and currently employs 711 full-time employees. The firm's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The firm's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. The company is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. The company has around 16 clinical-stage investigational medicines (wholly owned and partnered), which range in development stage from Phase I to Phase III. The firm's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MMP7, GSK-4532990, Fazirsiran, GSK5637608, ARO-CFB, ARO-INHBE, ARO-C3, ARO-PNPLA3, ARO-DUX4, ARO-DM1 and ARO-ATXN2.
What is the stock price of ARROWHEAD PHARMACEUTICALS IN today?
The current stock price of ARWR is 70.105 USD. The price increased by 1.43% in the last trading session.
Does ARWR stock pay dividends?
ARWR does not pay a dividend.
What is the ChartMill rating of ARROWHEAD PHARMACEUTICALS IN stock?
ARWR has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
How many employees does ARROWHEAD PHARMACEUTICALS IN have?
ARROWHEAD PHARMACEUTICALS IN (ARWR) currently has 711 employees.
When does ARROWHEAD PHARMACEUTICALS IN (ARWR) report earnings?
ARROWHEAD PHARMACEUTICALS IN (ARWR) will report earnings on 2026-02-05.